![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Nivalis Cystic Fibrosis Candidate Garners FDA Fast Track Status
Nivalis Cystic Fibrosis Candidate Garners FDA Fast Track Status
February 25, 2016
Nivalis Therapeutics has snapped up FDA fast track designation for its N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator protein.
Data is expected from the candidate’s Phase 2 trial in the second half of 2016. The treatment also recently won orphan drug status for cystic fibrosis.
Upcoming Events
-
21Oct